Update on glasdegib in acute myeloid leukemia – broadening horizons of Hedgehog pathway inhibitors
Numerous new emerging therapies, including oral targeted chemotherapies, have recently entered the therapeutic arsenal against acute myeloid leukemia (AML). The significant shift toward the use of these novel therapeutics, administered either alone or in combination with intensive or low-intensity c...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2022-03-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/acph-2022-0007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832573917367107584 |
|---|---|
| author | Fersing Cyril Mathias Fanny |
| author_facet | Fersing Cyril Mathias Fanny |
| author_sort | Fersing Cyril |
| collection | DOAJ |
| description | Numerous new emerging therapies, including oral targeted chemotherapies, have recently entered the therapeutic arsenal against acute myeloid leukemia (AML). The significant shift toward the use of these novel therapeutics, administered either alone or in combination with intensive or low-intensity chemotherapy, changes the prospects for the control of this disease, especially for elderly patients. Glasdegib, an oral Hedgehog pathway inhibitor, showed satisfactory response rates associated with moderate toxicity and less early mortality than standard induction regimens in this population. It was approved in November 2018 by the FDA and in June 2020 by the EMA for use in combination with low-dose cytarabine as a treatment of newly-diagnosed AML in patients aged ≥ 75 and/or unfit for intensive induction chemotherapy. The current paper proposes an extensive, up-to-date review of the preclinical and clinical development of glasdegib. Elements of its routine clinical use and the landscape of ongoing clinical trials are also stated. |
| format | Article |
| id | doaj-art-a75a0365f24a434498e63f20f2883b84 |
| institution | Kabale University |
| issn | 1846-9558 |
| language | English |
| publishDate | 2022-03-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj-art-a75a0365f24a434498e63f20f2883b842025-02-02T02:10:55ZengSciendoActa Pharmaceutica1846-95582022-03-0172193410.2478/acph-2022-0007Update on glasdegib in acute myeloid leukemia – broadening horizons of Hedgehog pathway inhibitorsFersing Cyril0Mathias Fanny1University of Montpellier, Montpellier Cancer Institute (ICM), Montpellier, FranceAix Marseille Univ, Pharmacy Department Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Marseille, FranceNumerous new emerging therapies, including oral targeted chemotherapies, have recently entered the therapeutic arsenal against acute myeloid leukemia (AML). The significant shift toward the use of these novel therapeutics, administered either alone or in combination with intensive or low-intensity chemotherapy, changes the prospects for the control of this disease, especially for elderly patients. Glasdegib, an oral Hedgehog pathway inhibitor, showed satisfactory response rates associated with moderate toxicity and less early mortality than standard induction regimens in this population. It was approved in November 2018 by the FDA and in June 2020 by the EMA for use in combination with low-dose cytarabine as a treatment of newly-diagnosed AML in patients aged ≥ 75 and/or unfit for intensive induction chemotherapy. The current paper proposes an extensive, up-to-date review of the preclinical and clinical development of glasdegib. Elements of its routine clinical use and the landscape of ongoing clinical trials are also stated.https://doi.org/10.2478/acph-2022-0007glasdegibpf-04449913pf-913acute myeloid leukemiahedgehog pathwaysmoothened |
| spellingShingle | Fersing Cyril Mathias Fanny Update on glasdegib in acute myeloid leukemia – broadening horizons of Hedgehog pathway inhibitors Acta Pharmaceutica glasdegib pf-04449913 pf-913 acute myeloid leukemia hedgehog pathway smoothened |
| title | Update on glasdegib in acute myeloid leukemia – broadening horizons of Hedgehog pathway inhibitors |
| title_full | Update on glasdegib in acute myeloid leukemia – broadening horizons of Hedgehog pathway inhibitors |
| title_fullStr | Update on glasdegib in acute myeloid leukemia – broadening horizons of Hedgehog pathway inhibitors |
| title_full_unstemmed | Update on glasdegib in acute myeloid leukemia – broadening horizons of Hedgehog pathway inhibitors |
| title_short | Update on glasdegib in acute myeloid leukemia – broadening horizons of Hedgehog pathway inhibitors |
| title_sort | update on glasdegib in acute myeloid leukemia broadening horizons of hedgehog pathway inhibitors |
| topic | glasdegib pf-04449913 pf-913 acute myeloid leukemia hedgehog pathway smoothened |
| url | https://doi.org/10.2478/acph-2022-0007 |
| work_keys_str_mv | AT fersingcyril updateonglasdegibinacutemyeloidleukemiabroadeninghorizonsofhedgehogpathwayinhibitors AT mathiasfanny updateonglasdegibinacutemyeloidleukemiabroadeninghorizonsofhedgehogpathwayinhibitors |